Levels of the MicroRNA MiR-145 Predict Likelihood of Breast Cancer Recurrence
By LabMedica International staff writers Posted on 07 Nov 2022 |
A recent study found that increased levels of the biomarker miR-145 (a microRNA) was linked to reduced risk of breast cancer recurrence following surgery.
While long-term outcomes have improved for patients with breast cancer, 20-30% will still develop recurrence, and identifying these patients remains a challenge. In this regard, investigators at the University of Galway (Republic of Ireland) examined whether miRNAs could predict which breast cancer patients were more likely to have a recurrence of the disease.
MicroRNAs (miRNAs) comprise a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation. In addition to miRNAs playing an essential role in tumor development, dysregulation of certain miRNAs has been associated with many different diseases, such as dementia and cardiovascular conditions.
For this study, the investigators obtained blood samples from 124 breast cancer patients (with median age of 55.0 years) at diagnosis and while they were undergoing chemotherapy, and assessed their outcomes almost nine years later. Predetermined miRNAs were quantified from patient whole bloods using RT-qPCR, and miRNA expression profiles were correlated with recurrence-free (RFS), disease-free (DFS), and overall (OS) survival.
Results revealed that increased miR-145 expression greater than 0.222 was associated with improved RFS. In addition, increased miR-145 expression midway through the treatment regimen predicted improved DFS. Thus, increased miR-145 expression correlated with improved outcomes in early-stage breast cancer. However, no miRNAs correlated with overall survival.
First author Dr. Matthew G. Davey, a surgeon at the University of Galway, said, “We showed that increased expression of this biomarker, which was measured in patients’ blood samples during chemotherapy, actually predicted their long-term oncological outcome. We can predict those who are likely to suffer recurrence and those who will be free of recurrence.”
The predictive value of MiR-145 was discussed in the November 3, 2022, online edition of the Journal of the American College of Surgeons.
Related Links:
University of Galway
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans